Besifovir

Besifovir (LB80331), a parent agent converted by LB80380 (HY-19447A), further metabolizes to its active form, LB80317 (HY-106235) . Besifovir is an orally active, novel antiviral agent against hepatitis B virus (HBV) [1][2].

Product Specifications

CAS Number

[441785-25-7]

Product Name Alternative

LB80331

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HBV

Type

Reference compound

Related Pathways

Anti-infection

Applications

Neuroscience-Neuromodulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/besifovir.html

Purity

98.0

Solubility

DMSO : 250 mg/mL (ultrasonic) |H2O : ≥ 100 mg/mL

Smiles

NC1=NC=C2N=CN(CC3(OCP(O)(O)=O)CC3)C2=N1

Molecular Formula

C10H14N5O4P

Molecular Weight

299.22

Precautions

H302, H315, H319, H335

References & Citations

[1]Jung JA, et al. Pharmacokinetic comparison of the maleate and free base formulations of LB80380, a novel nucleotide analog, in healthy male volunteers. Int J Clin Pharmacol Ther. 2012 Sep;50 (9) :657-64.|[2]Yuen MF, et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther. 2006;11 (8) :977-83.|[3]Lung-Yi Mak, et al. Pharmacokinetic evaluation of besifovir for the treatment of HBV infection. Expert Opin Drug Metab Toxicol. 2018 Jan;14 (1) :101-106.